JAMES C YAO to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications JAMES C YAO has written about Clinical Trials, Phase III as Topic.
Connection Strength
1.247
-
Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist. 2013; 18(5):525-32.
Score: 0.369
-
In reply. Oncologist. 2013; 18(11):1240-1.
Score: 0.361
-
Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. Cancer. 2021 Aug 01; 127(15):2674-2682.
Score: 0.160
-
Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. J Clin Oncol. 2015 Sep 10; 33(26):2914-9.
Score: 0.108
-
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 01; 29(7):934-43.
Score: 0.079
-
Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology (Williston Park). 2008 Dec; 22(14):1617-23; discussion 1623-4, 1629.
Score: 0.068
-
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol. 2021 Aug; 17(24):3151-3162.
Score: 0.040
-
Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas. 2021 02 01; 50(2):130-137.
Score: 0.039
-
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst. 2013 Jul 03; 105(13):954-9.
Score: 0.023